{"name":"Gil Yosipovitch","slug":"gil-yosipovitch","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizAJBVV95cUxObEM2bkxFbGlObjl1QTRyRXUxUXJCUnlqT0g4RGpQSTNLc3QtTHRWbFpCWUZCXzNCTzBGcUo5c0dYcmVtQXRpamZFNENzb0ZmTWFvS3lGbWZ1YTFmU2VKRGlFaC1UaUtKYUZzRElLeGJoQ1F2MWJpZE85aHJCVzNXUU1IOW12RWJYa056bWhHRTlPSlo3M3lzd0pKYTZVX3ZxZjJITzM1Mm5ZSG5CZ3BlMHllYzJieGh1aEJac1dxN2ZfOUFpYjZjdHlVMXlmRlh2d253Z1dRY3ItZ1Z4Y1ZZNzRIdFZBWjJ6VGVwczhPdkV6aEZQTlJQakNmUnFXWmJTWVAwQXBNWEM2eVJuY25uckF5R202M094NDF5dkljODY0LVc1dlF0bDh3TWpIWmdTaEZzdERicE9pbmt5aDZuN3MxQUs2TzFPQ1ZQWg?oc=5","date":"2026-02-10","type":"pipeline","source":"Managed Healthcare Executive","summary":"A conversation about nighttime itch with Gil Yosipovitch, M.D., dermatology professor at Miller School of Medicine at the University of Miami and the director of the Miami Itch Center - Managed Health","headline":"A conversation about nighttime itch with Gil Yosipovitch, M.D., dermatology professor at Miller School of Medicine at th","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTFBVYXdEUTYxSm50R0EzTTNZSkpPN05uTUNlZDNybjF4MFdHNVp5NnR1LVNEbzNtVzBfRUc3X3ppX2Y5d1NlNmJlQkFmdEpEOERDUUtNU3c5a3ljNHdfRk9hM1Brbw?oc=5","date":"2025-11-08","type":"pipeline","source":"Wiley Online Library","summary":"Journal of the European Academy of Dermatology and Venereology - Wiley Online Library","headline":"Journal of the European Academy of Dermatology and Venereology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOMFVmczRrcWotLW9welMzSWZHWUF0QUxVMDBFTjFJRy16VnJieWlKTURaTUNuWU95WklfNXZNVmpVTGJIdklaRXl6NHBqT3MtcXFsM1ZEdG15NmdTcjNKQ0tNVXcxU052T0twQ3o2ZkV6YUp6YWRvSWdCWTJ3NEk2NVJaMTBFeldPa3ppTTNfaTNsYXc?oc=5","date":"2024-06-07","type":"pipeline","source":"ajmc.com","summary":"Dr Gil Yosipovitch: Biologics Have Changed the World of CSU Care - ajmc.com","headline":"Dr Gil Yosipovitch: Biologics Have Changed the World of CSU Care","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQQ3RfZzlOaEExODE5dURMR203WkNCYmJ0Uy1HcHFTaDBZOUVVNHhTUUtJaTVFMG9FaDdMYVAxeVpDZUpDM01LYmJWUUFnRXZhZ0Z3amM5SENSMHpLLXc0VEp2eDdVVVQwdGRLNFNkMEgyN1ltRkhHeGZmaHFrdjF1U0hCaHpKbnVFOVR4a1htUzBXVHJHOU5TcWtLNXp5aENFc0l0Ui1sMFdwNGdJWXlFZjhfODVjUXpwX3FEcnQteF9BTXYtWGc?oc=5","date":"2023-11-06","type":"pipeline","source":"Healio","summary":"Remibrutinib safe, effective for chronic spontaneous urticaria over 52 weeks - Healio","headline":"Remibrutinib safe, effective for chronic spontaneous urticaria over 52 weeks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1xZWZaRzU0cHdwS2JYc05wX2JidDNOM0ZZUWZ2T3hCY1N5X2RiWFFHUFpVeXlyOEZkOGVwcWRpZ1d2ZlFUOEwxenc5bm1vZTM2LWZxdC16UEhXNmxIZnBV?oc=5","date":"2023-05-04","type":"trial","source":"nature.com","summary":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials - nature.com","headline":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPOWtVUU9LcTExOElaQzd5X3NsRlRnYXhuZHBpeVltLTcweEY0V1RfZUNmTUNscV9mY3ZCRldxWW9rNEIzVnJFMTFSbG1FU1hicGd5LTFqRFhkY0hXcjA3ZG1oUDFfcS1YTDgwTUNDdTZmbVdHbkJzYi1Dd3lFNTFaSXFpcjNvWnN0Q3E0?oc=5","date":"2023-04-03","type":"pipeline","source":"University of Miami","summary":"Scratching for an Explanation for Psoriatic Itchy Scalp - University of Miami","headline":"Scratching for an Explanation for Psoriatic Itchy Scalp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQek5uTmF0Y2hjS3B1YWJIelVTbWQxMmkyQm4xYUZFZG5OZm5BaTd0cUw4ZVpDRTVfdjFPd0tfNUFRaUo3aTdxSEp3VmY1Q3dEalJ5Qm4yN0tTcTFDc0dXRzRuRkVibkM4aUdpVW1fX05DWVRTbVJBa19Qb0gtWV96cUF0SlhzY1RlcmZsMXhLMmhSenpWcDFFTDd6SC02Mmg2WWRGWVZIMVFhNHRwVGFzRGFDVlI4TGV0VkxORVdGRk1MMnhXNDNDVDBIX28ycTRUTW12ZVFMTQ?oc=5","date":"2022-10-17","type":"pipeline","source":"Healio","summary":"Remibrutinib ‘very effective’ in treating moderate to severe chronic spontaneous urticaria - Healio","headline":"Remibrutinib ‘very effective’ in treating moderate to severe chronic spontaneous urticaria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE1TYW1tcDd1UEZmVjhiNFU1aEN6M1A3NWpaZkdQeTF2OFJzbDBhbDlHR242TFBmT0VQVGRsY0FYQTZSc0NnYUR2V3UyZHQ5UVFGdDZ0T0RwUmtfMWRFcnBuNGp2RQ?oc=5","date":"2021-05-25","type":"pipeline","source":"Wiley Online Library","summary":"The pruritogenic role of the type 2 immune response in diseases associated with chronic itch - Wiley Online Library","headline":"The pruritogenic role of the type 2 immune response in diseases associated with chronic itch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTFBSVlY4b0xuYVJjdFlOTkdaaDVPdV9iOXVudXBFWmMxS3l4Rk5EZktIMkF3T0pyR2Y3OTBjbzEyQWxoT0diYVRpaHV1d0VBX2JKbmJfV04zbw?oc=5","date":"2016-08-30","type":"pipeline","source":"nature.com","summary":"Galderma pursues 'itchy cytokine' by licensing antibody from Roche's Chugai - nature.com","headline":"Galderma pursues 'itchy cytokine' by licensing antibody from Roche's Chugai","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFAtZUJyZDgyUkZJeUMzZHlIYnJnVVByUWxKazBfX1d2dmx3aTFnbmQyOV9zN0NHYVdFdjYxcjVhRnFjSXA0d2dJMWVzRTJGaVVyLXN1QkRFLXhDWmRIT2JJ?oc=5","date":"2013-04-25","type":"pipeline","source":"NEJM","summary":"Chronic Pruritus - NEJM","headline":"Chronic Pruritus","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}